Pretreatment anti-Müllerian hormone predicts for loss of ovarian function after chemotherapy for early breast cancer☆

@inproceedings{Anderson2013PretreatmentAH,
  title={Pretreatment anti-M{\"u}llerian hormone predicts for loss of ovarian function after chemotherapy for early breast cancer☆},
  author={Richard A. Anderson and M Rosendahl and Thomas W. Kelsey and David A. Cameron},
  booktitle={European journal of cancer},
  year={2013}
}
AIM Improving survival for women with early breast cancer (eBC) requires greater attention to the consequences of treatment, including risk to ovarian function. We have assessed whether biochemical markers of the ovarian reserve might improve prediction of chemotherapy related amenorrhoea. METHODS Women (n=59, mean age 42.6 years [(range 23.3-52.5]) with eBC were recruited before any treatment. Pretreatment ovarian reserve markers (anti-Müllerian hormone [AMH], follicle-stimulating hormone… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 36 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 40 REFERENCES

Similar Papers

Loading similar papers…